Loading...
•
Dec 31, 2021
Amneal Q4 2021 Earnings Report
Amneal reported strong financial results driven by generic new product launches and growth in promoted specialty products.
Key Takeaways
Amneal Pharmaceuticals, Inc. reported Q4 2021 net revenue of $537 million, a GAAP net loss of $6 million, and an adjusted diluted EPS of $0.18. The company's performance was driven by generic new product launches and growth in promoted specialty products.
Q4 2021 Net Revenue was $537 million.
GAAP Net Loss was $6 million; Diluted Loss per Share was $0.04.
Adjusted Net Income was $54 million.
Adjusted Diluted EPS was $0.18.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Specialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal provides 2022 financial guidance of $2.15 to $2.25 billion in net revenue and $540 to $560 million in adjusted EBITDA.
Positive Outlook
- Net revenue: $2.15 billion - $2.25 billion
- Adjusted EBITDA: $540 million - $560 million
- Adjusted diluted EPS: $0.80 - $0.85
- Operating cash flow: $225 million - $250 million
- Weighted average diluted shares outstanding: Approximately 307 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income